Cary Street Partners Investment Advisory LLC Increases Holdings in Edwards Lifesciences Co. (NYSE:EW)

Cary Street Partners Investment Advisory LLC lifted its position in Edwards Lifesciences Co. (NYSE:EWFree Report) by 13.1% in the 4th quarter, HoldingsChannel.com reports. The fund owned 5,409 shares of the medical research company’s stock after buying an additional 627 shares during the period. Cary Street Partners Investment Advisory LLC’s holdings in Edwards Lifesciences were worth $412,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the business. Turtle Creek Wealth Advisors LLC bought a new stake in shares of Edwards Lifesciences in the 4th quarter valued at about $34,000. Operose Advisors LLC grew its holdings in Edwards Lifesciences by 247.0% in the third quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock worth $44,000 after purchasing an additional 452 shares during the last quarter. SRS Capital Advisors Inc. increased its position in shares of Edwards Lifesciences by 292.6% during the third quarter. SRS Capital Advisors Inc. now owns 636 shares of the medical research company’s stock worth $44,000 after purchasing an additional 474 shares in the last quarter. NBC Securities Inc. purchased a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at $52,000. Finally, ORG Partners LLC purchased a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at $66,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

NYSE:EW opened at $86.46 on Wednesday. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67. The company has a 50 day moving average price of $90.06 and a 200-day moving average price of $80.21. Edwards Lifesciences Co. has a 1-year low of $60.57 and a 1-year high of $96.12. The firm has a market cap of $52.10 billion, a price-to-earnings ratio of 37.27, a price-to-earnings-growth ratio of 3.56 and a beta of 1.10.

Edwards Lifesciences (NYSE:EWGet Free Report) last released its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The company had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.58 billion. Equities research analysts forecast that Edwards Lifesciences Co. will post 2.77 EPS for the current year.

Insider Buying and Selling

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Friday, May 10th. The shares were sold at an average price of $87.81, for a total value of $439,050.00. Following the sale, the vice president now owns 47,750 shares of the company’s stock, valued at approximately $4,192,927.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, VP Daveen Chopra sold 8,200 shares of the business’s stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $86.74, for a total transaction of $711,268.00. Following the completion of the sale, the vice president now directly owns 22,750 shares in the company, valued at $1,973,335. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Friday, May 10th. The shares were sold at an average price of $87.81, for a total value of $439,050.00. Following the completion of the transaction, the vice president now directly owns 47,750 shares of the company’s stock, valued at $4,192,927.50. The disclosure for this sale can be found here. In the last 90 days, insiders sold 213,340 shares of company stock valued at $18,816,952. 1.27% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

EW has been the topic of several recent analyst reports. Piper Sandler upped their target price on Edwards Lifesciences from $85.00 to $88.00 and gave the company a “neutral” rating in a research report on Friday, April 26th. StockNews.com upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Monday, April 29th. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research note on Thursday, March 7th. OTR Global upgraded shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research note on Tuesday, March 26th. Finally, Oppenheimer lifted their price objective on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a research note on Monday, March 18th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $93.88.

Check Out Our Latest Stock Report on EW

Edwards Lifesciences Profile

(Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Further Reading

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EWFree Report).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.